HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $105
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $100 to $105.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $100 to $105.